Literature DB >> 21907437

Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study.

Miranda E M C Christianen1, Cornelis Schilstra, Ivo Beetz, Christina T Muijs, Olga Chouvalova, Fred R Burlage, Patricia Doornaert, Phil W Koken, C René Leemans, Rico N P M Rinkel, Marieke J de Bruijn, G H de Bock, Jan L N Roodenburg, Bernard F A M van der Laan, Ben J Slotman, Irma M Verdonck-de Leeuw, Hendrik P Bijl, Johannes A Langendijk.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this large multicentre prospective cohort study was to identify which dose volume histogram parameters and pre-treatment factors are most important to predict physician-rated and patient-rated radiation-induced swallowing dysfunction (RISD) in order to develop predictive models for RISD after curative (chemo) radiotherapy ((CH) RT).
MATERIAL AND METHODS: The study population consisted of 354 consecutive head and neck cancer patients treated with (CH) RT. The primary endpoint was grade 2 or more swallowing dysfunction according to the RTOG/EORTC late radiation morbidity scoring criteria at 6 months after (CH) RT. The secondary endpoints were patient-rated swallowing complaints as assessed with the EORTC QLQ-H&N35 questionnaire. To select the most predictive variables a multivariate logistic regression analysis with bootstrapping was used.
RESULTS: At 6 months after (CH) RT the bootstrapping procedure revealed that a model based on the mean dose to the superior pharyngeal constrictor muscle (PCM) and mean dose to the supraglottic larynx was most predictive. For the secondary endpoints different predictive models were found: for problems with swallowing liquids the most predictive factors were the mean dose to the supraglottic larynx and radiation technique (3D-CRT versus IMRT). For problems with swallowing soft food the mean dose to the middle PCM, age (18-65 versus >65 years), tumour site (naso/oropharynx versus other sites) and radiation technique (3D-CRT versus IMRT) were the most predictive factors. For problems with swallowing solid food the most predictive factors were the mean dose to the superior PCM, the mean dose to the supraglottic larynx and age (18-65 versus >65 years). And for choking when swallowing the V60 of the oesophageal inlet muscle and the mean dose to the supraglottic larynx were the most predictive factors.
CONCLUSIONS: Physician-rated and patient-rated RISD in head and neck cancer patients treated with (CH) RT cannot be predicted with univariate relationships between the dose distribution in a single organ at risk and an endpoint. Separate predictive models are needed for different endpoints and factors other than dose volume histogram parameters are important as well.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21907437     DOI: 10.1016/j.radonc.2011.08.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  71 in total

1.  Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.

Authors:  Jeffrey M Vainshtein; Dominic H Moon; Felix Y Feng; Douglas B Chepeha; Avraham Eisbruch; Matthew H Stenmark
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 2.  Revisiting the dose constraints for head and neck OARs in the current era of IMRT.

Authors:  N Patrik Brodin; Wolfgang A Tomé
Journal:  Oral Oncol       Date:  2018-09-08       Impact factor: 5.337

3.  Treatment planning evaluation and optimization should be biologically and not dose/volume based.

Authors:  Joseph O Deasy; Charles S Mayo; Colin G Orton
Journal:  Med Phys       Date:  2015-06       Impact factor: 4.071

Review 4.  Systematic review of dose--volume correlates for structures related to late swallowing disturbances after radiotherapy for head and neck cancer.

Authors:  Fréderic Duprez; Indira Madani; Bruno De Potter; Tom Boterberg; Wilfried De Neve
Journal:  Dysphagia       Date:  2013-02-22       Impact factor: 3.438

5.  18F-FDG Metabolic Tumor Volume: Association with Short- and Long-Term Feeding Tube Use in Head and Neck IMRT.

Authors:  James E Jackson; Nigel J Anderson; Maureen Rolfo; Morikatsu Wada; Michal Schneider; Michael Poulsen; Maziar Fahandej; Anna Huynh; Sze Ting Lee; Daryl Lim Joon; Vincent Khoo
Journal:  Dysphagia       Date:  2018-09-28       Impact factor: 3.438

Review 6.  Treatment of late sequelae after radiotherapy for head and neck cancer.

Authors:  Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Treat Rev       Date:  2017-07-18       Impact factor: 12.111

7.  Feeding Tube Utilization in Patients with Salivary Gland Malignancies.

Authors:  Diane Wenhua Chen; Jan S Lewin; Li Xu; Stephen Y Lai; G Brandon Gunn; Clifton David Fuller; Abdallah S R Mohamed; Aasheesh Kanwar; Erich M Sturgis; Katherine A Hutcheson
Journal:  Otolaryngol Head Neck Surg       Date:  2016-10-03       Impact factor: 3.497

Review 8.  Treatment de-intensification strategies for head and neck cancer.

Authors:  Jacqueline R Kelly; Zain A Husain; Barbara Burtness
Journal:  Eur J Cancer       Date:  2016-10-15       Impact factor: 9.162

9.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

10.  Dysphagia after definitive radiotherapy for head and neck cancer. Correlation of dose-volume parameters of the pharyngeal constrictor muscles.

Authors:  L Deantonio; L Masini; M Brambilla; F Pia; M Krengli
Journal:  Strahlenther Onkol       Date:  2013-01-16       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.